<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Options for parenteral venous thromboembolism (VTE) prophylaxis in patients with cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Options for parenteral venous thromboembolism (VTE) prophylaxis in patients with cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Options for parenteral venous thromboembolism (VTE) prophylaxis in patients with cancer</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Hospitalized medical patients</td> <td class="subtitle1">Surgical patients (postoperative dosing*)</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Unfractionated heparin</td> </tr> <tr class="divider_bottom"> <td class="indent1">Unfractionated heparin</td> <td>5000 units once every 8 to 12 hours</td> <td>5000 units once every 8 to 12 hours beginning 6 to 24 hours postoperatively</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Low molecular weight (LMW) heparin</td> </tr> <tr> <td class="indent1">Dalteparin</td> <td>5000 units once daily</td> <td>5000 units once daily beginning 12 to 24 hours postoperatively</td> </tr> <tr> <td class="indent1">Enoxaparin</td> <td>40 mg once daily</td> <td>40 mg once daily beginning 12 to 24 hours postoperatively</td> </tr> <tr> <td class="indent1">Nadroparin<sup>¶</sup></td> <td>3800 anti-Xa units once daily</td> <td>3800 anti-Xa units once daily beginning 12 to 24 hours postoperatively</td> </tr> <tr class="divider_bottom"> <td class="indent1">Tinzaparin<sup>¶</sup></td> <td> <p>3500 anti-Xa units once daily</p> </td> <td>3500 anti-Xa units once daily beginning 12 to 24 hours postoperatively</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Fondaparinux</td> </tr> <tr> <td class="indent1">Fondaparinux</td> <td>2.5 mg once daily</td> <td> <p>2.5 mg once daily beginning 6 to 8 hours postoperatively or beginning on the morning of the day after surgery</p> </td> </tr> </tbody></table></div><div class="graphic_lgnd">These doses apply to VTE prophylaxis (not treatment) and are appropriate for patients with active cancer. Administration is by subcutaneous injection for all of the agents listed. Dose adjustments may be required for renal insufficiency or for obesity. For surgical patients, some surgeons will start prophylaxis preoperatively, depending on the specific procedure, bleeding risk, and thrombosis risk. Refer to UpToDate topics on VTE prevention in patients with cancer and VTE treatment in patients with cancer for further information including use of parenteral as well as oral anticoagulants.</div><div class="graphic_footnotes">VTE: venous thromboembolism.<br/>* Preoperative dosing may be appropriate in selected settings as long as there is no concern about bleeding with anticoagulation (eg, due to neuraxial anesthesia or spine surgery). Refer to UpToDate for details of anticoagulation management in individuals undergoing neuraxial anesthesia or procedures involving the central nervous system.<br/>¶ Not available in the United States.</div><div class="graphic_reference">Adapted from: Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31:2189.</div><div id="graphicVersion">Graphic 119688 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
